Basic Information
ADVATE 1000 IU Powder and Solvent for Solution for Injection
INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION
Regulatory Information
SIN13496P
July 16, 2008
Prescription Only
Therapeutic
INTRAVENOUS
August 10, 2023
May 30, 2025
XB02BD02
Company Information
TAKEDA PHARMACEUTICALS (ASIA PACIFIC) PTE. LTD.
TAKEDA PHARMACEUTICALS (ASIA PACIFIC) PTE. LTD.
Active Ingredients
rFVIII Octocog Alfa
Strength: 1000 IU
Detailed Information
Contraindications
**Contra-indications** Known hypersensitivity to any active substance, to excipients, or to mouse or hamster proteins.
Indication Information
**Indications** ADVATE is indicated for use in haemophilia A for prevention and control of haemorrhagic episodes. Patients with haemophilia A may be treated with ADVATE as perioperative management. ADVATE is not indicated in von Willebrand’s disease.